Hepatitis C treatment difficult in older patients (Hepatitis C Infection)
Hepatitis C treatment difficult in older patients
New Kerala - NEW YORK: Because of side effects, patients over the age of 60 with hepatitis C find it more difficult to stick with standard treatments than do their younger counterparts, according to a study in Japan. Impaired heart, lung and kidney function can
Inovio Biomedical to Develop Vaccine for Hepatitis C in Partnership
Genetic Engineering News - Inovio Biomedical Corporation (AMEX:INO), a late stage developer of cancer and other therapies using electroporation to deliver drugs and nucleic acids, announced today that it has signed an agreement with Swedish-based Tripep AB (The Stockholm
Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration
RxPG - "The initial success of our efforts to accelerate the HCV clinical trial program for Tarvacin Anti-Viral is gratifying in view of Tarvacin's promise as an important new treatment option for a number of viral infections, including chronic hepatitis C
Viral Hepatitis and HIV Coinfection
Medscape News - In Western countries, chronic HBV infection affects 5% to 10% of HIV-positive individuals. However, a larger proportion of the HIV-infected population has been exposed to HBV in the past. Isolated hepatitis B core antibody (anti-HBc) is more common
First-Time Generic Approvals: Copegus, Tegretol, Roxicodone
Medscape News - Jan. 24, 2006 The US Food and Drug Administration (FDA) approved in December 2005 first-time generic 200-mg formulations of ribavirin and carbamazepine tablets, and 15- and 30-mg formulations of oxycodone HCl tablets. First-time doses (ie, no
FDA Grants Fast Track Designation To Oral HCV Protease Inhibitor SCH
Medical News Today - Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational oral hepatitis C protease inhibitor (SCH 503034), currently in Phase II clinical development for the treatment
